AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01601665 — intervention group
Intervention type: DEVICE
Intervention: SN6AT8 Intraocular Lens
Description: Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
Study NCT01601665 — intervention group
Intervention type: DEVICE
Intervention: SN6AT9 Intraocular Lens
Description: Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
Study NCT01601665 — intervention group
Intervention type: DEVICE
Intervention: SN60WF Intraocular Lens
Description: Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
Study NCT00533286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzodiacepine
Description: diazepam (2 x 5 mg/ die)
Study NCT03410056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa administered as a subcutaneous injection.
Study NCT03410056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a subcutaneous injection.
Study NCT03835273 — intervention group
Intervention type: OTHER
Intervention: 3D motion capture system
Description: Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
Study NCT03835273 — intervention group
Intervention type: OTHER
Intervention: Incentive spirometry
Description: Incentive spirometry is a non-invasive device for assessment of pulmonary function.
Study NCT03835273 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system \[7,8\]
Study NCT02635984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
Study NCT02635984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
Study NCT03026491 — intervention group
Intervention type: OTHER
Intervention: Chewing evaluation
Description: Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
Study NCT00525980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Program
Description: Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor).
Study NCT00525980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Focus group discussion lasting about 60 to 90 minutes.
Study NCT00525980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Materials
Description: Printed materials will be given. The CD-ROM will be offered at the end of the study.
Study NCT00525980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
Study NCT02016183 — intervention group
Intervention type: DRUG
Intervention: Candesartan cilexetil / hydrochlorothiazide
Description: Candesartan cilexetil / hydrochlorothiazide combination tablets
Study NCT01230931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
Study NCT04404660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO1
Description: Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
Study NCT00271193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss counseling
Description: A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
Study NCT02581605 — intervention group
Intervention type: DEVICE
Intervention: Custom-made 'cutting block'
Description: To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
Study NCT01226030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 7.5mg
Description: M2ES 7.5mg
Study NCT01226030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 15mg
Description: M2ES 15mg
Study NCT01226030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 30mg
Description: M2ES 30mg
Study NCT01226030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 60mg
Description: M2ES 60mg
Study NCT06582537 — intervention group
Intervention type: PROCEDURE
Intervention: Participants sample collection
Description: A skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.
Study NCT02120196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
Study NCT02120196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: FDA approved:400mg once daily
Study NCT04760210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Treatment for this group is conventional physical therapy along with the bed rest.
Study NCT04760210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decompression Group
Description: Treatment for this is conventional physical therapy along with the spinal decompression.
Study NCT04760210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELDOA
Description: Treatment for this is conventional physical therapy along with the ELDOA.
Study NCT04061200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide, 1.34 mg/mL
Description: After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
Study NCT04061200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.34 mg/mL
Description: After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
Study NCT04061200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 1,34 mg/mL
Description: Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
Study NCT04061200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, 1,34 mg/mL
Description: Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
Study NCT04061200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
Study NCT04061200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
Study NCT05110911 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad
Description: Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
Study NCT05110911 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
Description: SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
Study NCT01011517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muscadine grape seed supplement
Description: Nature's Pearl 650 mg, two capsules daily
Study NCT01842529 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin injection
Study NCT01842529 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline injection
Study NCT01842529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Study NCT02573961 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: GaAlAs semiconductor diode Laser Phototherapy Device
Study NCT02573961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture
Description: GaAlAs semiconductor diode Laser Phototherapy Device
Study NCT02573961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: high protein low carbohydrate diet
Description: A tailored high protein/low carbohydrate/low caloric diet
Study NCT02573961 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: low caloric diet
Description: Tailored balanced low caloric diet
Study NCT02573961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low caloric diet
Description: Tailored balanced low caloric diet
Study NCT01318317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT01318317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV
Study NCT01318317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Lymphocyte Therapy
Description: Receive ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR
Study NCT01318317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01318317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT01318317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given IV
Study NCT01318317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00249431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
Study NCT00249431 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relapse Prevention Therapy
Description: Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
Study NCT00249431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Therapy
Description: Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
Study NCT04696536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
Study NCT04696536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Dental Association (ADA) Referenced Toothbrush
Description: Participants will brush teeth at least one minute with provided toothbrush twice daily.
Study NCT04696536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Hydroalcohol Mouth Rinse
Description: Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
Study NCT04696536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REACH Dental Floss
Description: Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
Study NCT04696536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)
Description: Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
Study NCT04151680 — intervention group
Intervention type: DRUG
Intervention: Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban
Description: Patients will receive intermittent treatment with a novel oral anticoagulant drug
Study NCT04151680 — intervention group
Intervention type: DRUG
Intervention: Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
Description: Patients will receive chronic treatment with a novel oral anticoagulant drug
Study NCT04105010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205
Description: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
Study NCT01493869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: 3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
Study NCT01011517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Muscadine grape seed supplement
Description: Nature's Pearl 650 mg, two capsules daily
Study NCT00834210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone
Description: Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
Study NCT01658761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy
Description: Surgery
Study NCT00112125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIMIZER System
Study NCT02502825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methacholine
Description: methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
Study NCT02502825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wright Nebulizer
Description: nebulized for 2 minutes with an output of 0.13ml/min
Study NCT00834210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene
Description: Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
Study NCT04238078 — intervention group
Intervention type: DRUG
Intervention: Contraceptive
Description: Oral contraceptive pill
Study NCT04177082 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study NCT01547390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT03454074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving
Description: Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
Study NCT01547390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05024825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
Study NCT05024825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone, acetaminophen and ibuprofen
Description: Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
Study NCT03454074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education about healthy brain aging behaviors provided.
Study NCT03454074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education about healthy brain aging behaviors provided.
Study NCT00882050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 0.27 ng/kg/min
Description: Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Study NCT00882050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 0.41 ng/kg/min
Description: Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Study NCT00914810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: 2000 I.U. daily for 6 weeks
Study NCT00914810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) daily for 6 weeks
Study NCT02307851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine
Study NCT02307851 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator TIV
Study NCT02502825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devilbiss646 Nebulizer
Description: nebulized for 2 minutes with an output of 0.13ml/min
Study NCT01954108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid sodium salt
Study NCT02862431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study NCT02983786 — intervention group
Intervention type: DRUG
Intervention: Indocyanine Green
Description: ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
Study NCT00763633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6
Description: high dose of vitamin B6
Study NCT00763633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6
Description: low vitamin B6
Study NCT02862431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study NCT01954108 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ESWT
Study NCT01042093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 5mg/ml (49.25 ml)